---
title: Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational
  status for non-squamous PD-L1 high (≥50%) NSCLC in the German National Network Genomic
  Medicine Lung Cancer (nNGM)
date: '2023-12-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38096950/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231215170616&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: G12C/TP53 co-mutations identify a subset of patients with
  a very favorable long-term survival with ICI monotherapy, mediated by highly active
  IFNγ signaling in a pro-inflammatory ...'
disable_comments: true
---
CONCLUSION: G12C/TP53 co-mutations identify a subset of patients with a very favorable long-term survival with ICI monotherapy, mediated by highly active IFNγ signaling in a pro-inflammatory ...